Clinical Trials Logo

Recurrent Desmoid Fibromatosis clinical trials

View clinical trials related to Recurrent Desmoid Fibromatosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04851119 Recruiting - Melanoma Clinical Trials

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Start date: November 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

NCT ID: NCT04195399 Active, not recruiting - Clinical trials for Desmoid Fibromatosis

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Start date: October 7, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.